New Approaches to Neuroblastoma Therapy Consortium

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, New Approaches to Neuroblastoma Therapy Consortium sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).

23 total trials 2 currently recruiting 16 completed early-phase tilt top decile by trial count

New Approaches to Neuroblastoma Therapy Consortium: 23 sponsored US clinical trials, 2 recruiting.

New Approaches to Neuroblastoma Therapy Consortium sponsors 23 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 16 completed. 0 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Neuroblastoma, with 8 trials.

Top-decile sponsor footprint

New Approaches to Neuroblastoma Therapy Consortium ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 75/100

16 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

23 total, page 1 of 1

RECRUITING Phase 2

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

NCT06450041
RECRUITING

Neuroblastoma Biology Study

NCT01587300
ACTIVE NOT RECRUITING Phase 1

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

NCT02573896
ACTIVE NOT RECRUITING

Neuroblastoma Precision Trial

NCT02868268
ACTIVE NOT RECRUITING Phase 1

Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma

NCT02298348
NOT YET RECRUITING Phase 2

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

NCT07261241
COMPLETED Phase 1

MIBG With Dinutuximab +/- Vorinostat

NCT03332667
COMPLETED Phase 1

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

NCT03107988
TERMINATED Phase 1

SF1126 for Patients With Relapsed or Refractory Neuroblastoma

NCT02337309
COMPLETED Phase 2

131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat

NCT02035137
COMPLETED Phase 1

N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan

NCT02030964
COMPLETED Phase 1

Study of MLN8237 in Combination With Irinotecan and Temozolomide

NCT01601535
COMPLETED Phase 1

N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma

NCT01019850
COMPLETED Phase 1

N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

NCT00885326
COMPLETED Phase 1

N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma

NCT00509353
COMPLETED Phase 1

N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma

NCT00295919
COMPLETED Phase 2

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

NCT00253435
COMPLETED Phase 1

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

NCT00093353
COMPLETED Phase 1

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

NCT00083135
COMPLETED Phase 1

N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma

NCT00084422
COMPLETED Phase 1

N99-02: Melphalan and Buthionine Sulfoximine

NCT00005835
COMPLETED Phase 1

N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma

NCT00005978
COMPLETED Phase 1

Chemotherapy in Treating Children With Neuroblastoma

NCT00002730

Phase Distribution

PhaseTrial count
Phase 1 17
Phase 2 4

Therapeutic Areas

Neuroblastoma 8

What is open in the New Approaches to Neuroblastoma Therapy Consortium pipeline

2 recruiting of 23 indexed (9% open); 16 completed (70%).

Phase mix: 0 late (III/IV) vs 21 early (I/II) (early-phase heavy).

Top condition: Neuroblastoma (8 trials), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

New Approaches to Neuroblastoma Therapy Consortium: open-pipeline peers nationwide

Peers matched on 23 registered trials and 9% open enrollment, not the therapeutic-area sidebar.

New Approaches to Neuroblastoma Therapy Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 22.922.92323.1 0%5%10%15%20%25% Total trials Recruiting share New Approaches to Neuroblastoma Therapy ConsortiumAMAG PharmaceuticalsAtriCureCara TherapeuticsCraig L Slingluff, JrIowa State UniversityRhythm PharmaceuticalsSwedish Orphan BiovitrumUniversity of Nevada, Reno
New Approaches to Neuroblastoma Therapy Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

New Approaches to Neuroblastoma Therapy Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 23 trials (± recruiting share)

Sponsors near 9% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this New Approaches to Neuroblastoma Therapy Consortium page

23 registered trials is a research-attention snapshot, not an endorsement of New Approaches to Neuroblastoma Therapy Consortium or any single study.

  • 2 of New Approaches to Neuroblastoma Therapy Consortium's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Neuroblastoma is the condition New Approaches to Neuroblastoma Therapy Consortium studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Neuroblastoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

New Approaches to Neuroblastoma Therapy Consortium pipeline card: 23 registered trials from official public datasets.Report a data error.